Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014
This page provides an overview of the opinions adopted at the July 2014 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.
Five new medicines recommended for approval
The CHMP has recommended granting marketing authorisations for two new medicines for the treatment of various rare cancers of the blood, Imbruvica (ibrutinib) and Zydelig (idelalisib). Please see the press release in the grid below for more information.
Granting a marketing authorisation to Xultophy (insulin degludec/liraglutide) for the treatment of diabetes mellitus has also been recommended.
The CHMP recommended granting a marketing authorisation for Accofil (filgrastim), a biosimilar medicine intended for the treatment of neutropenia.
The generic medicine Busulfan Fresenius Kabi (busulfan) was also recommended for authorisation for conditioning treatment prior to conventional haematopoietic progenitor cell transplantation.
Seven recommendations on extensions of therapeutic indications
The Committee recommended extensions of indications for Baraclude, Busilvex, Ecalta, Humira, Ozurdex, RoActemra and Xgeva.
Outcome of review on emergency contraceptives
The CHMP has concluded its review of emergency contraceptives containing levonorgestrel and ulipristal acetate.
Withdrawal of application
The application for a marketing authorisation for Neofordex has been withdrawn. For more information, please see question-and-answer document in the grid below.
Agenda and minutes
The agenda of the July 2014 meeting is published on the EMA website. The minutes of the meeting will be published during the week following the next meeting of the CHMP which will take place from 22-25 September 2014. Minutes of the June 2014 CHMP meeting will be published next week.
CHMP statistics
Key figures from the July 2014 CHMP meeting are represented in the graphic below.
Positive recommendations on new medicines
| Name of medicine | Imbruvica |
|---|---|
| International non-proprietary name (INN) | ibrutinib |
| Marketing-authorisation applicant | Janssen-Cilag International NV |
| Therapeutic indication | Treatment of relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukaemia |
| More information |
Summary of opinion for Imbruvica
|
| Press release: European Medicines Agency recommends approval of two new treatment options for rare cancers |
| Name of medicine | Xultophy |
|---|---|
| INN | insulin degludec / liraglutide |
| Marketing-authorisation applicant | Novo Nordisk A/S |
| Therapeutic indication | Treatment of type 2 diabetes mellitus |
| More information |
Summary of opinion for Xultophy
|
| Name of medicine | Zydelig |
|---|---|
| INN | idelalisib |
| Marketing-authorisation applicant | Gilead Sciences International Ltd |
| Therapeutic indication | Treatment of patients with chronic lymphocytic leukaemia and patients with refractory follicular lymphoma |
| More information |
Summary of opinion for Zydelig
|
| Press release: European Medicines Agency recommends approval of two new treatment options for rare cancers |
Positive recommendation on new generic medicine
| Name of medicine | Busulfan Fresenius Kabi |
|---|---|
| INN | busulfan |
| Marketing-authorisation applicant | Fresenius Kabi Oncology Plc |
| Therapeutic indication | Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation |
| More information |
Summary of opinion for Busulfan Fresenius Kabi
|
Positive recommendation on new biosimilar medicine
| Name of medicine | Accofil |
|---|---|
| INN | filgrastim |
| Marketing-authorisation applicant | Accord Healthcare Ltd |
| Therapeutic indication | Treatment of neutropenia |
| More information |
Summary of opinion for Accofil
|
Positive recommendations on extensions of therapeutic indications
| Name of medicine | Baraclude |
|---|---|
| INN | entecavir |
| Marketing-authorisation applicant | Bristol-Myers Squibb Pharma EEIG |
| More information |
Summary of opinion for Baraclude
|
| Name of medicine | Busilvex |
|---|---|
| INN | busulfan |
| Marketing-authorisation applicant | Pierre Fabre Médicament |
| More information |
Summary of opinion for Busilvex
|
| Name of medicine | Ecalta |
|---|---|
| INN | anidulafungin |
| Marketing-authorisation applicant | Pfizer Limited |
| More information |
Summary of opinion for Ecalta
|
| Name of medicine | Humira |
|---|---|
| INN | adalimumab |
| Marketing-authorisation applicant | AbbVie Ltd |
| More information |
Summary of opinion for Humira
|
| Name of medicine | Ozurdex |
|---|---|
| INN | dexamethasone |
| Marketing-authorisation applicant | Allergan Pharmaceuticals Ireland |
| More information |
Summary of opinion for Ozurdex
|
| Name of medicine | RoActemra |
|---|---|
| INN | tocilizumabum |
| Marketing-authorisation applicant | Roche Registration Ltd |
| More information |
Summary of opinion for RoActemra
|
| Name of medicine | Xgeva |
|---|---|
| INN | denosumab |
| Marketing-authorisation applicant | Amgen Europe B.V. |
| More information |
Summary of opinion for Xgeva
|
Public-health recommendation
| Name of medicine | Emergency contraceptives |
|---|---|
| INN | levonorgestrel / ulipristal acetate |
| More information | Emergency contraceptives |
Withdrawal of application
| Name of medicine | Neofordex |
|---|---|
| INN | dexamethasone acetate |
| Marketing-authorisation applicant | Laboratoires Ctrs - Boulogne Billancourt |
| More information |
Questions and answers on Neofordex
|
Other updates
|
Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures
|
|
Opinions on safety variations
|
| Start of Community reviews |
|
Scientific advice and protocol assistance
|
|
Guidelines and concept papers adopted
|
|
Overview of invented names reviewed in July 2014 by the Name Review Group (NRG)
|
|
Organisational matters
|
| Opinions on consultation procedures on ancillary medicinal substances in medical devices |